The TMPRSS2:ERG (T2E) gene fusion is the most common rearrangement in prostate cancer (PCa). It is unknown if these molecular subtypes have a different etiology. We evaluated aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in association with T2E fusion status. METHODS: Subjects were from a population-based case-control study of PCa. T2E fusion status for prostatectomy cases (n = 346) was determined by fluorescence in situ hybridization. Medication use was determined from questionnaires. Logistic regression, controlling for age, race, PCa family history and PSA screening, was used to evaluate the association of T2E fusion status according to medication use. RESULTS: T2E fusion was present in 171 (49%) cases, with younger cases more likely to be fusion positive (Po 0.01). Current aspirin use was associated with a 37% risk reduction of T2E-positive tumors (adjusted odds ratio (OR) 0.63, 95% confidence interval 0.43-0.93). Aspirin use was not associated with T2E negative PCa (adjusted OR 0.99, 0.69-1.42). There were no associations between PCa fusion status and use of nonaspirin NSAIDs or acetaminophen. CONCLUSIONS: Aspirin was associated with a significant reduction in the relative risk of T2E fusion positive, but not T2E negative, PCa. As inflammation and androgen pathways are implicated in prostate carcinogenesis, additional studies of anti-inflammatory medications in relation to these PCa subtypes are warranted.
INTRODUCTION
Prostate cancer (PCa) is a common malignancy, and there is interest in identifying potential chemoprevention agents. The disease is also heterogeneous in terms of its clinical features and biological behavior, and numerous strategies have been examined for their ability to stratify more homogeneous subsets of patients. The TMPRSS2:ERG (T2E) gene fusion is the most common somatic gene rearrangement in PCa, found in~50% of PCa cases. [1] [2] [3] [4] The gene fusion is between TMPRSS2, a gene encoding a serine protease whose expression is regulated by androgens, and ERG, a known oncogene involved in cell proliferation. The fusion of these two genes results in enhanced androgen stimulation of the ERG oncogene. 1 Aspirin has been found to be consistently associated with a lower risk for development of PCa. [5] [6] [7] [8] [9] [10] In a prior analysis we reported a modest reduction in the relative risk for PCa associated with aspirin use, but did not consider the cases' T2E fusion status. 5 To date, there have been few studies evaluating whether environmental or genetic factors are associated with T2E gene fusion status. 11 Information on the interplay of T2E fusion, prostate cancer and aspirin use may also shed light on the etiology of PCa. The exact mechanism of the inverse association between aspirin use and the development of PCa has not been completely elucidated. However, aspirin functions as an anti-inflammatory medication, 12 and there is a well-supported relationship between inflammation and PCa. 13, 14 In this analysis, we stratified PCa cases on the basis of T2E fusion status to assess whether the association with aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) use differed in subgroups defined by this somatic change. Nonaspirin NSAIDs and acetaminophen were examined to determine if the antiinflammatory effects were for the entire class of anti-inflammatory medications, or if the effects were aspirin specific.
MATERIALS AND METHODS

Study population
The study population is derived from men who participated in a prior population-based case-control study of PCa. 15 Eligible cases (n = 1327) were residents of King County, Washington with histologically confirmed PCa (identified from the Seattle-Puget Sound SEER cancer registry), diagnosed between 1 January 2002 and 31 December 2005. Of identified eligible men, 75% (n = 1001) agreed to participate. Cases included in this analysis were those who underwent radical prostatectomy (n = 472) and consented to collection of tumor tissue (n = 366), which was used to make tumor microarrays. Male residents of King County, Washington with no history of PCa were recruited as controls and identified using random digit telephone dialing. Controls were frequency matched to cases by 5-year age groups and enrolled evenly throughout the study period. Complete household census information of the 24 106 residential telephone numbers contacted was obtained for 81%. Of men who met the study eligibility criteria as a control, 63% (n = 942) completed the study interview.
Data collection
In-person interviews were conducted by trained staff for collecting information on demographic and lifestyle factors, medical and family history and PCa screening history (PSA and digital rectal exam). Body mass index was determined from self-reported height and weight (1 year prior to reference date: date of diagnosis for cases and a randomly assigned date for controls that approximated the distribution of cases' diagnosis dates).
The study questionnaire also queried details of specific classes of medication usage, including dates of use and duration of use for each episode of use. Participants were provided a comprehensive list of medications containing aspirin, nonaspirin NSAIDs and acetaminophen (both prescription and over-the-counter) and asked whether they had ever used any of the medications at least once a week for 3 months or longer. Participants were then asked for start and end dates of each aspirin, nonaspirin NSAID or acetaminophen-containing medication they reported using on a regular basis. Alternatively, participants could provide age of starting or stopping an aspirin, nonaspirin NSAID or acetaminophencontaining medication. Current use was defined as use at the reference date. Former use was defined as use for at least once a week for 3 months or longer, but not at the reference date. Duration of aspirin, nonaspirin NSAID or acetaminophen use was then determined for each individual based on these data. First, only those who were current users of aspirin, nonaspirin NSAIDs or acetaminophen were considered. Men were then grouped based on total duration of use as never users, 0.1-2.5 years, 2.6-4.9 years, 4.0-9.9 years and ⩾ 10 years.
Construction of TMAs
Tissue microarray (TMA) construction was performed as previously reported. 16 Formalin-fixed paraffin embedded tumor tissue blocks from radical prostatectomy samples were used to make H&E slides, which were reviewed by a prostate pathologist who marked areas containing ⩾ 75% tumor tissue. Two 1-mm tumor tissue cores were taken from these areas and embedded in recipient blocks for construction of TMAs.
Fluorescence in situ hybridization
Identification of the T2E genetic rearrangement was determined using an ERG gene 'break-apart' assay as previously described. 17 Probe labeling was performed by random priming and a two-color fluorescence in situ hybridization technique was used. Goat anti-FITC Alexa488 antibodies (Life Technologies, Carlsbad, CA, USA) were used to amplify the green FITC signals. Pictures were acquired using Axioplan 2 Imaging System (Carl Zeiss, Oberkochen, Germany) with Metafer Software (MetaSystems, Altlussheim, Germany). DAPI-Prescan (×10 magnification) of the whole TMA slide was used to identify the core positions. Core identification numbers were assigned using a TMA tool implemented in Metafer. Each spot was scanned at × 40 magnification, in a grid of 6 × 9 = 54 fields. Each field was photographed in at least three different focus planes with filters for FITC and Cy3. Referring layer and filter captures were then merged into one final three-colored image per field. After undergoing hybridization, each tissue core was evaluated by two separate individuals to determine if the specimen was T2E positive or negative. If there was disagreement, the specimen underwent further review until consensus was reached. Cores with o 25% evaluable material were excluded (n = 22) leaving 346 cases available for T2E analyses. Cores were considered positive if multiple cells contained the T2E rearrangement.
Statistical analysis
Demographic and pathologic characteristics were compared between cases with and without T2E fusion status with χ 2 -tests. Polytomous logistic regression was performed to determine the odds ratio as an estimate of the relative risk for the two case groups defined by T2E fusion status to controls. Age adjusted and multivariate models were performed with aspirin, nonaspirin NSAID or acetaminophen use as the exposure of interest. Variables adjusted for in the multivariate model included age at reference date, race, first-degree family history of PCa, PCa screening within 5 years prior to diagnosis (cases) or referent date (controls). Odds ratios (ORs) and 95% confidence intervals (95% CI) are reported. All analyses were performed with Stata SE/12 (College Station, TX, USA).
RESULTS
Tumor tissue was available for 346 cases and the T2E fusion was present in 171 (49%). Differences in selected demographic, environmental/lifestyle, medical and tumor characteristics are shown in Table 1 . The proportion of PCa cases with the T2E fusion declined with age (P o 0.01). In cases under the age of 50 years, 66% were fusion positive, compared with 24% of men of ages 70-74 years. The presence of the fusion was more commonly seen in men with lower grade tumors (52 and 53% of Gleason 2 − 6 and Gleason 3+4 tumors) than in higher grade tumors (26 and 44% of Gleason 4+3 and Gleason 8 − 10 tumors), respectively, P = 0.03. A family history of PCa, smoking status, body mass index (grouped by the World Health Organization categories) and PSA screening history were not associated with fusion status in this data set. The demographics and other features of the controls (n = 942) are also shown in Table 1 . Table 2 shows the ORs for PCa stratified by T2E fusion status compared with controls according to aspirin, nonaspirin NSAIDs and acetaminophen usage. Current use of aspirin was reported by 30% of cases with fusion-positive tumors, and the Given the association between aspirin use and PCa risk, we further explored duration of aspirin use (Table 3 ). There was a duration effect for aspirin use in T2E fusion-positive tumors. When compared with those who never used aspirin, the risk reduction for T2E fusion-positive tumors for current users with 410 years of aspirin use (multivariate-adjusted OR 0.46, 95% CI 0.24-0.88) was greater than the risk reduction for T2E fusion-positive tumors for current users with 5 to 9.9 years of aspirin use (multivariateadjusted OR 0.54, 95% CI 0.30-0.98). There was a non-significant risk reduction for T2E fusion-positive tumors for current users with o5 years of aspirin use. There was no association found between T2E fusion-negative tumors for any duration of aspirin use.
DISCUSSION
This study identified an association between aspirin use and a reduction in the risk of T2E-positive PCa. Among men reporting current aspirin use, there was a 37% reduction in the risk of developing T2E-positive tumors (OR 0.63, 95% CI 0.43-0.93), with a stronger risk reduction observed in relation to longer durations of use. No association with aspirin use was seen in T2E-negative PCa.
The T2E gene fusion is the most common somatic gene rearrangement seen in PCa. It has been shown to be present in 46-70% of prostate tumors. [1] [2] [3] [4] TMPRSS2 is a gene that is upregulated by androgen stimulation. ERG is a transcription factor that results in cell proliferation. The gene fusion causes androgen stimulation to drive cell proliferation.
Reactive oxygen species can create double-stranded DNA breaks and recruit leukocytes, which are necessary for initiation of an inflammatory response. [18] [19] [20] [21] [22] Inflammation has been identified as a factor that is potentially responsible for the transformation of normal prostate epithelium to prostate cancer. 13, 14 Prostate specimens displaying inflammation have also been shown to have higher expression of the androgen receptor. 23 Interestingly, androgen receptor levels have been shown to be elevated in PCa found in younger individuals. 24 Both T2E fusionpositive tumors and androgen receptor levels being increased in younger prostate cancer patients suggest that androgens have a role in the development of T2E-positive prostate cancer.
Aspirin, an anti-inflammatory medication, has been shown to decrease the amount of reactive oxygen species present within a cell. 12, 25, 26 This would limit the occurrence of the precursor events necessary for prostate tumorigenesis, and is a plausible mechanism for the observed risk reduction of T2E-positive PCa in relation to aspirin use. Investigations of the association between aspirin use and the risk of developing PCa have shown conflicting results. Some studies have found evidence of a decreased risk of PCa for men taking aspirin, [5] [6] [7] [8] [9] whereas other studies have not found any association. 27, 28 The results of our study may help explain some of these conflicting results. If aspirin reduces risk of T2E-positive PCa, but not T2E negative PCa, then the results of the previous studies may vary based on the T2E gene fusion status of the patients included. None of the previous studies examining the association between PCa and aspirin use have utilized molecular subtyping such as T2E gene fusion status to stratify patients.
To our knowledge this is the first study to report an association between aspirin use and a reduction in the risk of T2E-positive PCa. Further studies are needed to determine if our results are reproducible, and to identify any other potential etiological factors associated with T2E-positive versus negative PCa. The limitations of this study include self-reported aspirin use, which is subject to recall bias. However, because aspirin is available over-the-counter, self-report is necessary for capturing this exposure information. Cases included in the analysis consist of men who underwent surgery as primary treatment for PCa, and thus we do not have T2E status for patients who chose active surveillance or radiation treatment. There may be unmeasured variables that affect whether a patient is taking aspirin and which treatment modality is chosen. Further efforts to analyze T2E status on biopsy specimens would be informative.
In conclusion, our data indicate that aspirin use is associated with a decreased risk of developing T2E-positive PCa, but is not associated with T2E-negative PCa. Potentially, through a reduction in cellular stress and inflammation, aspirin use may protect against DNA strand breaks that are necessary for T2E fusion. Further studies are needed to confirm our results and determine the potential role of aspirin as a chemopreventive agent for T2E-positive PCa.
